Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Status:
Terminated
Trial end date:
2019-09-04
Target enrollment:
Participant gender:
Summary
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate
the efficacy and safety of pasireotide alone or in combination with cabergoline in patients
with Cushing's disease.